Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Revvity Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $48.32, while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals.
| EWU | RVTY | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $48.68 | $117.75 |
52-Week Low | $40.90 | $82.26 |
Market Cap | — | $12.91B |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU, the iShares MSCI United Kingdom ETF, trades at $48.33, down 0.33% on the day, with a bullish technical signal driven by moving averages. The ETF tracks UK large-cap equities, with recent institutional activity showing mixed positions. Key support and resistance cluster around $48-$49, while RSI levels indicate neutral momentum. Geopolitical tensions and oil price volatility influence FTSE 100 performance, as highlighted in recent financial news.
The outlook for EWU is cautiously optimistic, supported by technical strength but tempered by macroeconomic risks. Opportunities include exposure to UK market resilience, while risks involve Middle East tensions and inflation concerns. Investors should weigh institutional inflows against broader market volatility for balanced positioning.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
